<p>製藥行業在我們日常生活中扮演着至關重要的角色。從我們需要的救命藥物，到日常的止痛或過敏藥物，大型製藥公司在提供我們所需的藥物方面發揮着重要作用，讓我們能夠保持快樂和健康。</p>
<p>圍繞這一行業，大多數投資者的關注要麼是負面的（與美國高昂的藥品價格有關），要麼是放在創新治療各種退行性疾病上，如阿爾茨海默病、糖尿病治療、減肥藥物和各種癌症治療。許多這些特定業務線確實非常賺錢，並且對患者有着很高的內在和顯性價值，因此可以相應地收費。</p>
<p>因此，那些能夠建立可持續的藥物管道並繼續受益於專利和其他保護措施的公司，將有很多錢可賺。專家建議，整個製藥行業到 2028 年的預計收入可能達到 1.6 萬億美元，這意味着這是一個值得分一杯羹的大蛋糕。</p>
<p>對於那些尋找這一行業最佳投資機會的人，這裏是我目前的三大首選。</p>
<h2>本文要點：</h2>
<ul>
<li>大型製藥公司可能在新聞中聲名狼藉，但它們繼續產生可預測且持續增長的利潤。</li>
<li>以下是未來幾年中玩轉這一行業長期潛力的三種最大、最好的方式。</li>
<li>如果你正在尋找潛力巨大的股票，請務必獲取我們全新的 “下一個英偉達” 報告的免費副本。其中包括我們確信具有 10 倍潛力的軟件股票。</li>
</ul>
<h2>艾伯維（ABBV）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/10/imageForEntry31-0VG.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/10/imageForEntry31-0VG.jpg"/></p>
<p>艾伯維公司總部外的標誌</p>
<p><strong>艾伯維</strong>（NYSE: ABBV）是一家頂尖的製藥巨頭，今年股價飆升。該公司的股價今年上漲約 60%，更令人印象深刻的是，股價在過去五年裏飆升了超過 730%。這種回報是投資者可能期望從快速增長的初創公司而不是市值接近 8000 億美元的公司看到的。</p>
<p>艾伯維之所以聲名鵲起，主要源自其熱門藥物提爾齊帕肽，該藥物以蒙加羅的名義治療糖尿病，並最近獲得了減肥藥物澤普邦的批准。</p>
<p>據分析師預計，該藥物的銷售額預計將達到約 500 億美元，預計隨着時間的推移可能會增加其他適應症。我見過它對他人的影響，並可以證明這種藥物在其性質上是革命性的。但是，對於如此革命性的藥物，肯定會有來自其他公司的競爭，而艾伯維已經看到了這一點。</p>
<p>也就是説，鑑於目前的短缺和保險公司價格上漲的預期，這是一種在市場上肯定具有充足定價權的藥物。該公司繼續以令人印象深刻的銷售額吸引增長型投資者，截至 6 月 30 日的季度報告顯示，銷售額達到 113 億美元。這相當於同比增長 36%，年初至今增長 31%。</p>
<p>我認為，鑑於艾伯維強大的藥物管道，這種勢頭可以在長期內持續下去。這是我認為目前值得投資的長期贏家。</p>
<h2>黎利製藥（LLY）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/10/imageForEntry9-02k.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/10/imageForEntry9-02k.jpg"/></p>
<p>艾伯維辦公樓</p>
<p>在 7 月 25 日，製藥巨頭 <strong>艾伯維</strong>（NYSE: ABBV）是那些根據公司的免疫藥物銷售強勁業績而提高 2024 年利潤預測的頂級參與者之一。艾伯維報告的季度業績超過了華爾街的預期，推動其股價創下歷史新高。作為報告的一部分，這家藥品巨頭增加了 10 美分的盈利預期，預計本財年每股盈利在 10.71 美元至 10.91 美元之間。</p>
<p>這些業績確實令人印象深刻，但我認為公司整體股息概況並沒有得到足夠的關注。艾伯維股票目前的股息率為 3.2%，是我認為值得長期持有的分紅製藥巨頭之一。部分原因是這家藥品巨頭在過去十年裏將股息支付增加了 270%，遠遠超過大多數同行。因此，在這個高利潤空間中尋找收入的投資者肯定可以依靠這支股票獲得出色的總回報。</p>
<p>艾伯維繼續有效地重新投資其利潤，2019 年推出了治療牛皮癬的斯凱瑞茲和治療關節炎的林沃克，這兩者在同一時期共產生了 73 億美元的銷售額。從長期來看，這是我認為值得在這裏持有的頂級製藥股票。</p>
<h2>默克（MRK）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/05/imageForEntry9-umf.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/05/imageForEntry9-umf.jpg"/></p>
<p>默克辦公樓</p>
<p><strong>默克</strong>（NYSE: MRK）是另一家美國主要製藥公司，專注於提供各種疫苗和抗癌藥物。值得注意的是，截至去年，該公司的管道中有 52 種藥物，而且這個數字還在增長。此外，默克的主要抗癌藥物在過去一年中創造了 263 億美元的銷售額。這代表了 16% 的同比增長，並使公司在這一核心領域處於有利位置。</p>
<p>此外，該公司繼續通過收購早期藥物並將其打造成暢銷品來增強其產品組合。默克收購 EyeBio 開發視網膜治療藥物以及收購 Elanco 水產業務擴展其動物保健業務，鞏固了其在這些市場的領先地位。</p>
<p>該公司還通過在 2023 年投入 305 億美元用於研發，鞏固了其在行業中的領先地位。其龐大的基礎設施使得藥品和疫苗的生產成本更具競爭力，增強了其競爭優勢。分析師仍然持樂觀態度，預計未來 12 個月的中位價格目標為 140 美元，暗示着相對當前價格的 20% 上漲。</p>
<p>我認為這家頂級製藥公司將是長期贏家，但這不僅僅是我的看法。華爾街似乎也對此持樂觀態度。我喜歡這一點。</p>
<h2><strong>參加這個退休問卷，立即與顧問匹配（贊助內容）</strong></h2>
<p>您準備好退休了嗎？規劃退休可能讓人感到不知所措，這就是為什麼今天與一位受託人理財顧問討論您的目標可能是個好主意。</p>
<p>首先，從 SmartAsset 的這個退休問卷開始，它將在 5 分鐘內為您匹配最多 3 位服務您所在地區及周邊地區的理財顧問。Smart Asset 目前每月為超過 5 萬人提供匹配服務。</p>
<p>立即點擊這裏開始。</p>
<p>這篇文章首發於 24/7 Wall St.，介紹 2024 年 10 月值得購買的 3 家頂級製藥公司股票。</p>

禮來

艾伯維

<p>製藥行業對日常健康至關重要，創新治療方案備受投資者關注。專家預測，到 2028 年，該行業的收入可能達到 1.6 萬億美元。熱門股票選擇包括禮來（LLY），由於其糖尿病和減肥藥物 Mounjaro，今年股價上漲了 60%；以及艾伯維（ABBV），該公司提高了利潤預測，並提供 3.2% 的股息率。這兩家公司在一個利潤豐厚的市場中處於長期增長的有利位置</p>

<p>The pharmaceutical industry plays a crucial role in most of our everyday lives. From life-saving medication we need when we need it, to everyday pain remediation or allergy medications, big pharma companies have played a big role in providing the medicines we all need to stay happy and healthy on a daily basis.</p>
<div class="lb-trans"><p>製藥行業在我們日常生活中扮演着至關重要的角色。從我們需要的救命藥物，到日常的止痛或過敏藥物，大型製藥公司在提供我們所需的藥物方面發揮着重要作用，讓我們能夠保持快樂和健康。</p>
</div><p>Most investor attention around this sector has either been negative (tied to higher prices in the U.S.) or has been placed on innovative treatments for various degenerative diseases such as Alzheimer’s, diabetes treatments, weight loss drugs and various cancer treatments. Many of these particular business lines are certainly very lucrative, and have a high implicit and explicit value for their patients, and can be charged for accordingly.</p>
<div class="lb-trans"><p>圍繞這一行業，大多數投資者的關注要麼是負面的（與美國高昂的藥品價格有關），要麼是放在創新治療各種退行性疾病上，如阿爾茨海默病、糖尿病治療、減肥藥物和各種癌症治療。許多這些特定業務線確實非常賺錢，並且對患者有着很高的內在和顯性價值，因此可以相應地收費。</p>
</div><p>Thus, companies that are able to build out sustainable drug pipelines and continue to benefit from patents and other protective measures this sector benefits from, there’s a lot of money to be made. Experts suggest that the entire pharma sector could see projected revenues hit $1.6 trillion by 2028, meaning this is a big pie to try to take a bite out of.</p>
<div class="lb-trans"><p>因此，那些能夠建立可持續的藥物管道並繼續受益於專利和其他保護措施的公司，將有很多錢可賺。專家建議，整個製藥行業到 2028 年的預計收入可能達到 1.6 萬億美元，這意味着這是一個值得分一杯羹的大蛋糕。</p>
</div><p>For those looking for the best bets this sector has to offer, here are three of my top picks right now.</p>
<div class="lb-trans"><p>對於那些尋找這一行業最佳投資機會的人，這裏是我目前的三大首選。</p>
</div><h2>Key Points About This Article:</h2>
<ul>
<li>Big pharma companies may be getting a bad rep in the news, but they continue to pump out predictable and growing profits over time.</li>
<li>Here are three of the biggest and best ways to play the long-term potential growth of this sector in the coming years.</li>
<li>If you’re looking for some stocks with huge potential, make sure to grab a free copy of our <strong>brand-new “The Next NVIDIA” report</strong>. It features a software stock we’re confident has 10X potential.</li>
</ul>
<div class="lb-trans"><h2>本文要點：</h2>
<ul>
<li>大型製藥公司可能在新聞中聲名狼藉，但它們繼續產生可預測且持續增長的利潤。</li>
<li>以下是未來幾年中玩轉這一行業長期潛力的三種最大、最好的方式。</li>
<li>如果你正在尋找潛力巨大的股票，請務必獲取我們全新的 “下一個英偉達” 報告的免費副本。其中包括我們確信具有 10 倍潛力的軟件股票。</li>
</ul>
</div><h2>Eli Lilly (LLY)</h2>
<div class="lb-trans"><h2>艾伯維（ABBV）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/10/imageForEntry31-0VG.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2022/10/imageForEntry31-0VG.jpg"/></p>
<p>An Eli Lilly sign outside the company’s corporate offices</p>
<div class="lb-trans"><p>艾伯維公司總部外的標誌</p>
</div><p><strong>Eli Lilly</strong> (NYSE:LLY) is a top pharmaceutical giant that is absolutely rocketing higher this year. The company’s share price hassurged by approximately 60% this year, and even more impressively, the stock has skyrocketed more than 730% over the past five years. Those are the kinds of returns investors might expect to see from a fast-growing startup, not a company with a market capitalization near $800 billion.</p>
<div class="lb-trans"><p><strong>艾伯維</strong>（NYSE: ABBV）是一家頂尖的製藥巨頭，今年股價飆升。該公司的股價今年上漲約 60%，更令人印象深刻的是，股價在過去五年裏飆升了超過 730%。這種回報是投資者可能期望從快速增長的初創公司而不是市值接近 8000 億美元的公司看到的。</p>
</div><p>Eli Lilly’s ride to investor fame has largely stemmed from its popular drug, tirzepatide, which treats diabetes under the name Mounjaro and has recently been approved for weight loss as Zepbound.</p>
<div class="lb-trans"><p>艾伯維之所以聲名鵲起，主要源自其熱門藥物提爾齊帕肽，該藥物以蒙加羅的名義治療糖尿病，並最近獲得了減肥藥物澤普邦的批准。</p>
</div><p>This drug is expected to see peak sales of around $50 billion according to analysts, with expectations that additional indications could be added on over time. I’ve seen the impact on others and can vouch that this drug is revolutionary in its nature. But with such a revolutionary drug, there will most certainly be competition from others, which Eli Lilly is already seeing.</p>
<div class="lb-trans"><p>據分析師預計，該藥物的銷售額預計將達到約 500 億美元，預計隨着時間的推移可能會增加其他適應症。我見過它對他人的影響，並可以證明這種藥物在其性質上是革命性的。但是，對於如此革命性的藥物，肯定會有來自其他公司的競爭，而艾伯維已經看到了這一點。</p>
</div><p>That said, given current shortages and expectations of pricing increases for insurance companies, this is a drug that could certainly have plenty of pricing power in the market. The company has continued to attract growth investors with impressive sales, reporting $11.3 billion for the quarter ending June 30. This amounted to a 36% increase year-over-year, and a 31% rise year-to-date.</p>
<div class="lb-trans"><p>也就是説，鑑於目前的短缺和保險公司價格上漲的預期，這是一種在市場上肯定具有充足定價權的藥物。該公司繼續以令人印象深刻的銷售額吸引增長型投資者，截至 6 月 30 日的季度報告顯示，銷售額達到 113 億美元。這相當於同比增長 36%，年初至今增長 31%。</p>
</div><p>I think this momentum can continue over the long-term, given Eli Lilly’s strong drug pipeline. This is a long-term winner I think is worth the plump valuation right now.</p>
<div class="lb-trans"><p>我認為，鑑於艾伯維強大的藥物管道，這種勢頭可以在長期內持續下去。這是我認為目前值得投資的長期贏家。</p>
</div><h2>AbbVie (ABBV)</h2>
<div class="lb-trans"><h2>黎利製藥（LLY）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/10/imageForEntry9-02k.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2022/10/imageForEntry9-02k.jpg"/></p>
<p>An AbbVie office building</p>
<div class="lb-trans"><p>艾伯維辦公樓</p>
</div><p>On July 25, pharma giant <strong>AbbVie</strong> (NYSE:ABBV) was among the top players that raised their 2024 profit forecast following strong results driven by the company’s immunology drug sales. AbbVie reported quarterly results that surpassed Wall Street expectations, propelling its shares to a record high. As part of its report, the drug giant increased its earnings estimate by 10 cents, projecting between $10.71 and $10.91 per share for this fiscal year.</p>
<div class="lb-trans"><p>在 7 月 25 日，製藥巨頭 <strong>艾伯維</strong>（NYSE: ABBV）是那些根據公司的免疫藥物銷售強勁業績而提高 2024 年利潤預測的頂級參與者之一。艾伯維報告的季度業績超過了華爾街的預期，推動其股價創下歷史新高。作為報告的一部分，這家藥品巨頭增加了 10 美分的盈利預期，預計本財年每股盈利在 10.71 美元至 10.91 美元之間。</p>
</div><p>Those results certainly were impressive, but I don’t think enough attention has been paid to the company’s overall dividend profile. AbbVie stock currently yields 3.2%, and is among the dividend-paying pharma giants I think is worth owning for the long-term. That’s in part due to the fact this drug giant has increased increased its dividend payout by 270% over the past decade, far surpassing most of its peers. Thus, those looking for an income-generating investment in this highly-profitable space can certainly bank on this stock for excellent total returns.</p>
<div class="lb-trans"><p>這些業績確實令人印象深刻，但我認為公司整體股息概況並沒有得到足夠的關注。艾伯維股票目前的股息率為 3.2%，是我認為值得長期持有的分紅製藥巨頭之一。部分原因是這家藥品巨頭在過去十年裏將股息支付增加了 270%，遠遠超過大多數同行。因此，在這個高利潤空間中尋找收入的投資者肯定可以依靠這支股票獲得出色的總回報。</p>
</div><p>AbbVie continues to effectively reinvest its profits, launching Skyrizi for psoriasis and Rinvoq for arthritis in 2019, which together generated $7.3 billion in sales during the same period. Over the long-term, this is a top pharmaceutical stock I think is worth owning here.</p>
<div class="lb-trans"><p>艾伯維繼續有效地重新投資其利潤，2019 年推出了治療牛皮癬的斯凱瑞茲和治療關節炎的林沃克，這兩者在同一時期共產生了 73 億美元的銷售額。從長期來看，這是我認為值得在這裏持有的頂級製藥股票。</p>
</div><h2>Merck (MRK)</h2>
<div class="lb-trans"><h2>默克（MRK）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/05/imageForEntry9-umf.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2022/05/imageForEntry9-umf.jpg"/></p>
<p>A Merck office building</p>
<div class="lb-trans"><p>默克辦公樓</p>
</div><p><strong>Merck</strong>(NYSE:MRK) is another major U.S. pharmaceutical company that is focused on providing a range of vaccines and cancer care drugs. Notably, the company has 52 drugs in its pipeline as of last year, and the number is growing. Additionally, Merck’s top cancer drug generated $26.3 billion in sales over the past year. This represented 16% year-over-year growth, and positions the company well in this core segment.</p>
<div class="lb-trans"><p><strong>默克</strong>（NYSE: MRK）是另一家美國主要製藥公司，專注於提供各種疫苗和抗癌藥物。值得注意的是，截至去年，該公司的管道中有 52 種藥物，而且這個數字還在增長。此外，默克的主要抗癌藥物在過去一年中創造了 263 億美元的銷售額。這代表了 16% 的同比增長，並使公司在這一核心領域處於有利位置。</p>
</div><p>Furthermore, the company continues to enhance its portfolio via acquiring early-stage drugs and turning them into blockbusters. Merck’s acquisition of EyeBio to develop retinal treatments is among the key deals worth noting, as well as the company’s expansion of its Animal Health segment through the purchase of Elanco’s aqua business, reinforcing its leadership in these markets.</p>
<div class="lb-trans"><p>此外，該公司繼續通過收購早期藥物並將其打造成暢銷品來增強其產品組合。默克收購 EyeBio 開發視網膜治療藥物以及收購 Elanco 水產業務擴展其動物保健業務，鞏固了其在這些市場的領先地位。</p>
</div><p>The company also solidified its industry leadership with a $30.5 billion investment in research and development in 2023. Its expansive infrastructure enables cost-effective drug and vaccine production, enhancing its competitive advantage. Analysts remain optimistic, with a 12-month median price target of $140, suggesting a 20% upside from here.</p>
<div class="lb-trans"><p>該公司還通過在 2023 年投入 305 億美元用於研發，鞏固了其在行業中的領先地位。其龐大的基礎設施使得藥品和疫苗的生產成本更具競爭力，增強了其競爭優勢。分析師仍然持樂觀態度，預計未來 12 個月的中位價格目標為 140 美元，暗示着相對當前價格的 20% 上漲。</p>
</div><p>I think this top pharma stock will be a long-term winner, but that’s not just my view. Wall Street seems to be aboard this train. I like that.</p>
<div class="lb-trans"><p>我認為這家頂級製藥公司將是長期贏家，但這不僅僅是我的看法。華爾街似乎也對此持樂觀態度。我喜歡這一點。</p>
</div><h2><strong>Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)</strong></h2>
<div class="lb-trans"><h2><strong>參加這個退休問卷，立即與顧問匹配（贊助內容）</strong></h2>
</div><p>Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.</p>
<div class="lb-trans"><p>您準備好退休了嗎？規劃退休可能讓人感到不知所措，這就是為什麼今天與一位受託人理財顧問討論您的目標可能是個好主意。</p>
</div><p>Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.</p>
<div class="lb-trans"><p>首先，從 SmartAsset 的這個退休問卷開始，它將在 5 分鐘內為您匹配最多 3 位服務您所在地區及周邊地區的理財顧問。Smart Asset 目前每月為超過 5 萬人提供匹配服務。</p>
</div><p>Click here now to get started.</p>
<div class="lb-trans"><p>立即點擊這裏開始。</p>
</div><p>The post 3 Top Pharma Stocks to Buy in October 2024 appeared first on 24/7 Wall St..</p>
<div class="lb-trans"><p>這篇文章首發於 24/7 Wall St.，介紹 2024 年 10 月值得購買的 3 家頂級製藥公司股票。</p>
</div>

2024 年 10 月值得購買的三大製藥股票